Press Release-Viral Vector and Plasmid DNA Manufacturing Market to Reach Valuation of USD 1902.7 Million by 2028 - Increasing Advanced Therapies is Driving the Market

In terms of revenue, the Global Viral Vector and Plasmid DNA Manufacturing Market is expected to reach USD 1902.7 Million by 2028, growing at a Compound Annual Growth Rate (CAGR) of 16.1% from 2022 to 2028. With the increase in shift in the treatment paradigm of several life-threatening diseases through progressive therapies, there is a growing demand for viral vector-based vaccines for viral.

Key Findings:

• Under the vector type segment adeno associated Virus sub-segment is anticipated to dominate the segment for Viral Vector and Plasmid DNA Manufacturing Market and grow at a substantial Compound Annual Growth Rate (CAGR). The adenoviral vectors are considered safe, thus are progressively being employed across various research centers.
• The vaccinology sub-segment held a market significant share in 2021. This is the fastest segment growing in Viral Vector and Plasmid DNA Manufacturing Market. This is attributed to the increased employment of viral vectors in vaccine development due to their efficiency-related benefits.
• North America is the largest regional segment. The existence of a substantial number of centers and establishments that are related to the R&D of advanced therapies is one of the key contributing elements for the prominence of the region.

Some of key players in Viral Vector and Plasmid DNA Manufacturing Market include - Fujifilm Diosynth Biotechnologies (US), SIRION Biotech (Germany), Thermo Fisher Scientific (US), Merck KGaA Inc. (US), Cognate BioServices Inc. (Cobra Biologics) (US)​ are the major companies operating in Global Viral Vector and Plasmid DNA Manufacturing Market..

A rising number of patients opting for gene therapy is a primary factor driving the growth of the Viral Vectors and Plasmid DNA Manufacturing market. Gene therapy is a foremost field in medical science, which pledges new treatment outcomes for patients suffering from different diseases. pDNA is a prerequisite for the production of AAV, lentivirus, and other viral vector platforms. There is an expansion in several genetic disorders and contagious diseases across the globe. According to the UNAIDS statistics, in 2019, 38.0 million people worldwide are living with HIV and 1.7 million people became newly infected with HIV.

Genetically altered therapies have appeared as a favorable treatment strategy for various diseases, containing inherited disorders and specific viral infections. Demand for plasmid DNA is increasing steeply due to a boom in gene therapy development. Development of the global viral vector and plasmid DNA manufacturing market is driven by the rise in budget for R&D activities initiating gene therapy, rise in prevalence of cancer, viral infection, & genetic disorders, and growing awareness regarding gene therapy.

North America is expected to emerge as potential market for Viral Vector and Plasmid DNA Manufacturing Market. This is due to the high prevalence rate of cancer and modern healthcare structures. Adoption of experimental medicines and an increase in awareness about gene therapy are anticipated to boost the regional market. Additionally rapid industrialization in the area, an increase in disposable income, and a surge in management initiatives to modernize healthcare establishments.